AMD3100/培利西林通过 CXCL12-KRT19 涂层克服胰腺和结直肠癌细胞的免疫抑制。
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
机构信息
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Weill Cornell Medicine, New York, NY, USA.
出版信息
Br J Cancer. 2021 Jul;125(2):149-151. doi: 10.1038/s41416-021-01315-y. Epub 2021 Mar 26.
Abstract
A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4 mediates this response, and how cancer cells elicit it.
摘要
最近一项关于抑制趋化因子受体 CXCR4 对胰腺导管腺癌或结直肠癌患者免疫影响的 1 期临床研究表明，免疫细胞上 CXCR4 的刺激抑制了肿瘤内的免疫反应。在这里，我们讨论 CXCR4 如何介导这种反应，以及癌细胞如何引发这种反应。
相似文献
1
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
Br J Cancer. 2021 Jul;125(2):149-151. doi: 10.1038/s41416-021-01315-y. Epub 2021 Mar 26.
2
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970. doi: 10.1073/pnas.2013644117. Epub 2020 Oct 30.
3
PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.
Leukemia. 2019 May;33(5):1296-1301. doi: 10.1038/s41375-019-0428-6. Epub 2019 Feb 28.
4
A role for the CXCR4-CXCL12 axis in the little skate, Leucoraja erinacea.
Am J Physiol Regul Integr Comp Physiol. 2018 Aug 1;315(2):R218-R229. doi: 10.1152/ajpregu.00322.2017. Epub 2018 Apr 11.
5
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Br J Cancer. 2010 Nov 23;103(11):1671-9. doi: 10.1038/sj.bjc.6605968. Epub 2010 Nov 2.
6
CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Int J Nanomedicine. 2020 Aug 7;15:5701-5718. doi: 10.2147/IJN.S257527. eCollection 2020.
7
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Leuk Lymphoma. 2009 Oct;50(10):1676-86. doi: 10.1080/10428190903150847.
8
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
Transfusion. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.
9
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15.
10
Production of human embryonic kidney 293T cells stably expressing C-X-C chemokine receptor type 4 (CXCR4) as a screening tool for anticancer lead compound targeting CXCR4.
Life Sci. 2022 Aug 15;303:120661. doi: 10.1016/j.lfs.2022.120661. Epub 2022 May 26.
引用本文的文献
1
Development of a CXCR4 antagonistic peptide, P12, to suppress pancreatic cancer progress enhancing T cell responses and sensitizing cells to gemcitabine.
RSC Med Chem. 2025 Jul 19. doi: 10.1039/d5md00488h.
2
Cancer-associated fibroblasts: dual roles from senescence sentinels to death regulators and new dimensions in therapy.
Front Immunol. 2025 Jul 18;16:1635771. doi: 10.3389/fimmu.2025.1635771. eCollection 2025.
3
Inhibiting CXCR4 reduces immunosuppressive effects of myeloid cells in breast cancer immunotherapy.
Sci Rep. 2025 Feb 12;15(1):5204. doi: 10.1038/s41598-025-89882-5.
4
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3.
5
Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.
Cancers (Basel). 2024 Apr 11;16(8):1470. doi: 10.3390/cancers16081470.
6
Targeting neutrophils: Mechanism and advances in cancer therapy.
Clin Transl Med. 2024 Mar;14(3):e1599. doi: 10.1002/ctm2.1599.
7
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.
Mol Cancer. 2023 Oct 2;22(1):159. doi: 10.1186/s12943-023-01860-5.
8
Involvement of CXCL12/CXCR4 axis in colorectal cancer: a mini-review.
Mol Biol Rep. 2023 Jul;50(7):6233-6239. doi: 10.1007/s11033-023-08479-1. Epub 2023 May 23.
9
Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment.
Front Oncol. 2023 Apr 11;13:1116016. doi: 10.3389/fonc.2023.1116016. eCollection 2023.
10
Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis.
Mol Cancer. 2022 Dec 22;21(1):225. doi: 10.1186/s12943-022-01682-x.
Zotero 插件